# A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

Study · id `cardio:ct-nct01750190` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01750190](<https://clinicaltrials.gov/study/NCT01750190>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01750190

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 922 participants.

## Technical summary

Registry record NCT01750190. Randomized; quadruple masking; primary purpose treatment. Start 2012-11-05 (actual); primary completion 2018-09-24 (actual). Results posted on 2021-10-01.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 922 participants (enrolled count; ClinicalTrials.gov record NCT01750190, source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)
- Started: 2012-11-05 (actual) (ClinicalTrials.gov record NCT01750190, source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)
- Primary completion: 2018-09-24 (actual) (ClinicalTrials.gov record NCT01750190, source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)
- Completion: 2018-09-24 (actual) (ClinicalTrials.gov record NCT01750190, source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)
- Results first posted: 2021-10-01 (ClinicalTrials.gov record NCT01750190, source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Chile; Colombia; Hong Kong SAR China; Malaysia; Mexico; New Zealand; Peru; Philippines; Puerto Rico; Singapore; South Korea; Taiwan; Thailand (ClinicalTrials.gov record NCT01750190, source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01750190-2021-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
- Condition: CKD Anemia
- Intervention (Drug): Roxadustat
- Intervention (Drug): Placebo
- Lead sponsor: Kyntra Bio
- Lead sponsor class: INDUSTRY
- Collaborator: Astellas Pharma Europe B.V.
- Collaborator class: INDUSTRY
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Kyntra Bio (`cardio:org-kyntra-bio`)
- Registry lists this organization as a collaborator: Astellas Pharma Europe B.V. (`cardio:org-astellas-pharma-europe-b-v`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 905c5c6701949c0706ff906f75db4bec6ddd939b9964e38525677f8f5e75f350
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
